Menu Search
Equities

Pulmatrix Inc

2PU:DUS

Pulmatrix Inc

Actions
  • Price (EUR)5.75
  • Today's Change0.300 / 5.50%
  • Shares traded--
  • 1 Year change+263.46%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 18:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Pulmatrix, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other diseases with important unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders, such as acute migraine and serious lung diseases, such as chronic obstructive pulmonary disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). The Company’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes. The Company’s therapeutic candidates include PUR3100, PUR1800, and PUR1900. PUR3100 is the iSPERSE formulation of dihydroergotamine (DHE), for the treatment of acute migraine.

  • Revenue in USD (TTM)10.01m
  • Net income in USD-9.66m
  • Incorporated2013
  • Employees22.00
  • Location
    Pulmatrix Inc945 CONCORD STREET, SUITE 1217FRAMINGHAM 01701United StatesUSA
  • Phone+1 (781) 357-2333
  • Fax+1 (302) 636-5454
  • Websitehttps://www.pulmatrix.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		PULM:NAQ since
announced		Transaction
value
Cullgen IncAnnounced13 Nov 202413 Nov 2024Announced198.54%280.00m
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.